Making a case for the socioeconomic determinacy of survival in osteosarcoma tumor

Clinical Orthopaedics and Related Research

Volumn 471, Issue 3, 2013, Pages 784-791

  Nathan, Saminathan S ^a   Healey, John H ^b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE DISTRIBUTION; AMPUTATION; ASIAN; CANCER GRADING; CANCER SIZE; CANCER SURVIVAL; COHORT ANALYSIS; CONFERENCE PAPER; CONTROLLED STUDY; DATA BASE; EAST ASIAN; ETHNIC DIFFERENCE; FEMALE; FOREQUARTER AMPUTATION; HEALTH CARE DELIVERY; HEALTH CARE DISTRIBUTION; HEMIPELVECTOMY; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOSARCOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SEX DIFFERENCE; SINGAPORE; SOCIAL STATUS; SOCIOECONOMICS; UNITED STATES; WIDE EXCISION; ADOLESCENT; AGE; ARTICLE; BONE TUMOR; CANCER REGISTRY; CHI SQUARE DISTRIBUTION; CHILD; CROSS-SECTIONAL STUDY; ECONOMICS; ETHNOLOGY; INCOME; INFANT; KAPLAN MEIER METHOD; MORTALITY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; OSTEOTOMY; PATHOLOGY; PRESCHOOL CHILD; PROPORTIONAL HAZARDS MODEL; RACE; RETROSPECTIVE STUDY; SURVIVAL RATE; TIME; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGE FACTORS; AMPUTATION; BONE NEOPLASMS; CHI-SQUARE DISTRIBUTION; CHILD; CHILD, PRESCHOOL; CONTINENTAL POPULATION GROUPS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INCOME; INFANT; KAPLAN-MEIER ESTIMATE; MALE; MULTIVARIATE ANALYSIS; OSTEOSARCOMA; OSTEOTOMY; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SEER PROGRAM; SEX FACTORS; SINGAPORE; SOCIOECONOMIC FACTORS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

MLCS; MLOWN;

EID: 84875771616     PISSN: 0009921X     EISSN: 15281132     Source Type: Journal    
DOI: 10.1007/s11999-012-2575-1     Document Type: Conference Paper

References (24)

1. Bacci G, Briccoli A, Ferrari S, Longhi A, Mercuri M, Capanna R, Donati D, Lari S, Forni C, DePaolis M. Neoadjuvant chemotherapy for osteosarcoma of the extremity: long-term results of the Rizzoli's 4th protocol. Eur J Cancer. 2001;37:2030-2039.
2. Bacci G, Ferrari S, Longhi A, Picci P, Mercuri M, Alvegard TA, Saeter G, Donati D, Manfrini M, Lari S, Briccoli A, Forni C; Italian Sarcoma Group/Scandinavian Sarcoma Group. High dose ifosfamide in combination with high dose methotrexate, Adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group pilot study. J Chemother. 2002;14:198-206.
3. Bureau of Economic Analysis, US Department of Commerce; Per Capita Personal Income by State. Available at: http://bber.unm.edu/econ/us-pci.htm. 2004. Accessed November 25, 2004.
4. Enneking WF. Musculoskeletal Tumor Surgery. ed 1. New York, NY, USA: Churchill Livingstone; 1983.
5. Ganey PE, Thurman RG. Ethanol potentiates doxorubicin-induced inhibition of cell survival in cultured Chinese hamster ovary cells. Cancer Res. 1991;51:2036-2040.
6. Gherlinzoni F, Picci P, Bacci G, Campanacci D. Limb sparing versus amputation in osteosarcoma. Correlation between local control, surgical margins and tumor necrosis: Istituto Rizzoli experience. Ann Oncol. 1992;3(Suppl 2):S23-S27.
7. Greene FL. AJCC Cancer Staging Manual. ed. 6. New York, NY, USA: Springer-Verlag; 2002.
8. Guo W, Xu W, Huvos AG, Healey JH, Feng C. Comparative frequency of bone sarcomas among different racial groups. Chin Med J (Engl). 1999;112:1101-1104.
9. Huvos AG. Bone Tumors - Diagnosis, Treatment & Prognosis. ed. 2. Philadelphia, PA, USA: WB Saunders Co; 1991.
10. Huvos AG, Butler A, Bretsky SS. Osteogenic sarcoma in the American black. Cancer. 1983;52:1959-1965.
11. Huvos AG, Rosen G, Marcove RC. Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy en bloc resection, and prosthetic bone replacement. Arch Pathol Lab Med. 1977;101:14-18.
12. Jaffe HL. Tumors and Tumorous Conditions of the Bones and Joints. Philadelphia, PA, USA: Lea & Febiger; 1958.
13. Jaffe N. Recent advances in the chemotherapy of metastatic osteogenic sarcoma. Cancer. 1972;30:1627-1631.
14. Lai HC, Lai MP, Leung KS. Glucose-6-phosphate dehydrogenase deficiency in Chinese. J Clin Pathol. 1968;21:44-47.
15. Liu Y, Thurman RG. Potentiation of Adriamycin toxicity by ethanol in perfused rat liver. J Pharmacol Exp Ther. 1992;263:651-656.
16. Marcove RC, Mike V, Hajek JV, Levin AG, Hutter RV. Osteogenic sarcoma under the age of twenty-one. A review of one hundred and forty-five operative cases. J Bone Joint Surg Am. 1970;52:411-423.
17. Meyers PA, Heller G, Healey J, Huvos A, Lane J, Marcove R, Applewhite A, Vlamis V, Rosen G. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol. 1992;10:5-15.
18. Parekh HK, Sladek NE. NADPH-dependent enzyme-catalyzed reduction of aldophosphamide, the pivotal metabolite of cyclophosphamide. Biochem Pharmacol. 1993;46:1043-1052.
19. Rosen G, Nirenberg A, Caparros B, Juergens H, Kosloff C, Mehta BM, Marcove RC, Huvos AG. Osteogenic sarcoma: eight-percent, three-year, disease-free survival with combination chemotherapy (T-7). Natl Cancer Inst Monogr. 1981;56:213-220.
20. Simon MA, Aschliman MA, Thomas N, Mankin HJ. Limb-salvage treatment versus amputation for osteosarcoma of the distal end of the femur. J Bone Joint Surg Am. 1986;68:1331-1337.
21. Teng YS. Human liver aldehyde dehydrogenase in Chinese and Asiatic Indians: gene deletion and its possible implications in alcohol metabolism. Biochem Genet. 1981;19:107-114.
22. The Surveillance, Epidemiology, and End Results (SEER) Program. National Cancer Institute. Available at: http://seer.cancer.gov. 2004. Accessed November 18, 2004.
23. US Cancer Statistics Working Group. United States Cancer Statistics: 2000 Incidence and Mortality. Atlanta, GA, USA: US Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; 2000.
24. Zalupski MM, Rankin C, Ryan JR, Lucas DR, Muler J, Lanier KS, Budd GT, Biermann JS, Meyers FJ, Antman K. Adjuvant therapy of osteosarcoma - a Phase II trial: Southwest Oncology Group study 9139. Cancer. 2004;100:818-825.